NFKB1 and cancer: By mimicking this phosphorylated state, the S249/T252 peptide aims to disrupt the RB-NF-κB interaction and inhibit NF-κB-mediated PD-L1 transcription, thereby strengthening cancer immunity and overcoming immune evasion mechanisms triggered by both conventional and targeted therapies (Jin et al., 2019).